logo
Dozens killed by Israeli fire as they sought desperately needed aid in Gaza, Palestinian health ministry says

Dozens killed by Israeli fire as they sought desperately needed aid in Gaza, Palestinian health ministry says

CNNa day ago

At least 51 people were killed and more than 200 others injured by Israeli fire as they waited for aid trucks to arrive in Khan Younis in southern Gaza early Tuesday morning, the Palestinian Ministry of Health said.
The incident marks the highest reported number of people killed while seeking aid over the past few weeks in the enclave. In total, nearly 400 Palestinians have been killed near aid centers since Israel lifted an 11-week total blockade on Gaza and allowed a trickle of aid to enter, according to the health ministry.
The Israel Defense Forces (IDF) said in a Tuesday statement that 'a gathering was identified adjacent to an aid distribution truck that got stuck in the area of Khan Younis, and in proximity to IDF troops operating in the area.'
The IDF said it was 'aware of reports regarding a number of injured individuals from IDF fire following the crowd's approach,' that 'details of the incident are under review,' and that it 'regrets any harm to uninvolved individuals and operates to minimize harm as much as possible to them while maintaining the safety of our troops.'
One eyewitness, Mohammed Abu Abed, said that a group of people was hit by an airstrike. He told CNN: 'We were waiting for flour trucks. Suddenly, we were among the people and were hit by two missiles that tore apart people's bodies, remains, pieces of flesh everywhere. I don't know what to say; they killed the people, unarmed people who had nothing on them.'
'They went to bring bread for their children, just bread or flour. They killed us in cold blood,' Abu Abed said.
Video from the scene in Khan Younis on Tuesday shows dozens of bodies lying on the ground, covered in blood.
The latest scenes of death, violence and desperation underline a grim existence for over 2.1 million people living in Gaza – which the United Nations has warned is edging closer to famine.
Humanitarian organizations say that aid currently entering the enclave is only a tiny fraction of what is needed, with the controversial Gaza Humanitarian Foundation (GHF) – the main supplier of aid in Gaza – coming under global scrutiny since it opened its distribution points late last month.
Palestinians en route to GHF distribution sites have repeatedly been fired upon since its inception, according to the health ministry, with some 3,000 people injured in addition to the fatalities. On Tuesday, eight people were also killed after coming under Israeli fire near an aid distribution site west of Rafah, the ministry said.
CNN has reached out to the IDF for comment.
The GHF, an Israeli-US backed private contractor, has been criticized by multiple international aid agencies for setting up its distribution centers amid active combat zones. The organization has repeatedly said there has been no violence at their sites. But the GHF acknowledged earlier this month that there have been Palestinian casualties in the surrounding areas, which the organization described as 'well beyond our secure distribution site.' A spokesman referred further questions to the Israeli military.
On Tuesday, Volker Türk, the UN High Commissioner for Human Rights said on X: 'Israel has weaponized food and blocked lifesaving aid. I urge immediate, impartial investigations into deadly attacks on desperate civilians trying to reach food distribution centres.'
One of those killed in Khan Younis on Tuesday was a 20-year-old man, who had traveled there in hope of returning with food for his family.
Speaking through tears, his mother said: 'He didn't go for a picnic. He went to bring food for his siblings and father.'
Nearby, at Nasser Medical Complex, hospital staff said that the entire ward was crowded with casualties. Video from the hospital showed dozens of people arriving with wounds, with others inside the hospital waiting for treatment as they laid on the floor.
One intensive care doctor told Medical Aid for Palestinians (MAP), an aid organization based in the United Kingdom, that the hospital had received on Tuesday 'a large number of injured and killed from the Israeli army's targeting of aid distribution points in Khan Younis.'
'The situation here is catastrophic beyond imagination,' the doctor said, adding that the morgue was completely full and that additional bodies had been placed outside the building.
'We are trying our best, but the numbers are overwhelming,' he said.
CNN's Oren Liebermann contributing reporting.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ELISpot and Fluorospot Assay Market Set to Reach USD 528.30 Million by 2032, Driven by Immuno-Oncology Research and Diagnostic Innovation
ELISpot and Fluorospot Assay Market Set to Reach USD 528.30 Million by 2032, Driven by Immuno-Oncology Research and Diagnostic Innovation

Yahoo

time4 hours ago

  • Yahoo

ELISpot and Fluorospot Assay Market Set to Reach USD 528.30 Million by 2032, Driven by Immuno-Oncology Research and Diagnostic Innovation

SNS Insider Unveils Strategic Insights into the U.S. ELISpot and Fluorospot Assay Market's Rapid Growth—Valued at USD 79.68 Million in 2023—While the U.S. Commands Over 40% of the Global Share Amid Diagnostic Advancements in Immunology. Austin, June 18, 2025 (GLOBE NEWSWIRE) -- ELISpot and Fluorospot Assay Market Size & Growth Analysis: According to SNS Insider, the global ELISpot and Fluorospot Assay Market was valued at USD 290.92 million in 2023 and is projected to reach USD 528.30 million by 2032, growing at a CAGR of 6.85% during the forecast period of 2024–2032. The U.S. market alone was valued at USD 79.68 million in 2023, forecasted to climb to USD 138.33 million by 2032, with a CAGR of 6.32%.Get a Sample Report of ELISpot and Fluorospot Assay Market@ The growth trajectory is largely fueled by increasing applications in infectious disease diagnostics, cancer immunotherapy, and autoimmune disease research. As demand for highly sensitive immune response assays grows, these platforms are rapidly being adopted by hospitals, biotech firms, and academic labs. Market Overview The ELISpot and Fluorospot assays are gaining traction across immunological research and clinical diagnostics due to their precision in detecting immune responses. Widely utilized in vaccine development, autoimmune disease studies, and cancer immunotherapy, these assays are supported by the increasing demand for high-sensitivity diagnostics. The U.S. remains a key contributor to market growth, benefiting from strong research funding, a highly developed healthcare infrastructure, and the presence of major industry players. Globally, market expansion is further driven by the rising incidence of chronic and infectious diseases and the growing adoption of personalized medicine. Technological advancements in assay analyzers and kits are expected to fuel additional market momentum throughout the forecast period. Major Players Analysis Listed in this Report are: Becton, Dickinson, and Company (BD ELISPOT Assay System, BD FluoroSpot Assay Kit) U-CyTech biosciences (Human IFN-γ ELISPOT Kit, Monkey IL-4 FluoroSpot Kit) Cellular Technologies Limited (CTL) (ImmunoSpot Human IFN-γ ELISPOT Kit, ImmunoSpot Human IL-2/IL-4 FluoroSpot Kit) Mabtech AB (Human IFN-γ ELISpotPRO Kit, Human IL-2/IL-4 FluoroSpot Kit) Abcam (Human IFN-γ ELISPOT Kit, Human IL-17A/IL-22 FluoroSpot Kit) Oxford Immunotec ( Test, Test) Bio-Techne Corporation (Human IFN-γ ELISpot Kit, Human IL-10/IL-12 FluoroSpot Kit) Autoimmun Diagnostika GmbH (AID) (AID iSpot ELISPOT Plate Reader, AID iSpot Spectrum FluoroSpot Reader) Lophius Biosciences GmbH (T-Track ELISPOT Kit, T-Track CMV FluoroSpot Kit) Bio-Connect B.V. (Human TNF-α ELISPOT Kit, Human IL-5/IL-13 FluoroSpot Kit) Thermo Fisher Scientific (Mabtech Human IFN-γ ELISpot Kit, Mabtech Human IL-2/IL-4 FluoroSpot Kit) PerkinElmer Inc. (ATPlite Luminescence Assay System, LANCE Ultra TR-FRET Assay) R&D Systems (Human IFN-γ ELISPOT Kit, Human IL-17/IL-22 FluoroSpot Kit) Enzo Life Sciences (Human IFN-γ ELISPOT Kit, Human IL-4/IL-5 FluoroSpot Kit) MilliporeSigma (Merck KGaA) (ELISpot Plate Reader System, FluoroSpot Multi-Analyte Assay Kit) ImmunoDiagnostics Limited (Human IFN-γ ELISPOT Kit, Human IL-21/IL-22 FluoroSpot Kit) ALPCO (Human IFN-γ ELISPOT Kit, Human IL-10/IL-12 FluoroSpot Kit) RayBiotech Life, Inc. (Human IFN-γ ELISPOT Kit, Human IL-6/IL-8 FluoroSpot Kit) Cell Sciences (Human IFN-γ ELISPOT Kit, Human IL-2/IL-5 FluoroSpot Kit) ZellBio GmbH (Human IFN-γ ELISPOT Kit, Human IL-4/IL-10 FluoroSpot Kit) ELISpot and Fluorospot Assay Market Report Scope Report Attributes Details Market Size in 2023 USD 290.92 million Market Size by 2032 USD 528.30 million CAGR (2024–2032) 6.85% U.S. Market 2023 USD 79.68 million U.S. Forecast by 2032 USD 138.33 million Base Year 2023 Forecast Period 2024–2032 Key Regional Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis By Product The assay kits segment captured the highest market share of 48.56% in 2023. This is due to the extensive use of assay kits in research and diagnostic applications. The need for high-sensitivity detection in immunological studies also contributes to the growth of this segment. The segment of analyzers will be growing at the highest rate. The high demand for automated and high-throughput analyzers in research and laboratory settings is driving the growth of this segment. These analyzers improve accuracy and efficiency, leading to increasing demand in the market. By Application The diagnostic applications market held 65.41% of the market share in 2023. The growing incidence of infectious diseases, autoimmune diseases, and cancer has driven the demand for ELISpot and Fluorospot assays in clinical diagnostics. These assays provide accurate and early detection, leading to their popularity in diagnostic laboratories and healthcare facilities. The research applications segment is expected to witness the most rapid growth. The growing emphasis on immunological research, vaccine discovery, and T-cell monitoring in cancer and infectious disease research is propelling the growth of this segment. Growing funding and advances in technology are also driving its rapid growth. By End Use The hospitals and clinical laboratories segment accounted for the largest share of 47.25% in 2023. The rising need for sophisticated diagnostic equipment in healthcare facilities, as well as the rising number of hospital-based research studies, has supported the application of ELISpot and Fluorospot assays in hospitals and clinical labs. The biopharmaceutical and research institutes segment is expected to grow at the fastest rate. The growing investment in drug discovery and immunological research by academic institutions and pharmaceutical companies is fueling the demand for these assays in research settings. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ ELISpot and Fluorospot Assay Market Segmentation By Product Assay Kits Analyzers Ancillary Products By Application Research Applications Diagnostics Applications By End Use Hospital and Clinical Labs Academic and Research Institutes Biopharmaceutical Company Regional Insights North America dominated the worldwide market in 2023 with a share of 36.25%, driven by its well-developed healthcare infrastructure, robust research culture, and high prevalence of adoption of next-generation diagnostic technologies. The United States is particularly prominent because of high government and private investment in immunology and infectious disease research. The Asia-Pacific market is expected to have the highest growth rate until 2032. The major drivers include the growth of healthcare infrastructure, higher R&D spending, and an increasing prevalence of infectious diseases. Recent Developments February 2025: BD announced the separation of its Biosciences and Diagnostic Solutions business to enhance strategic focus and growth, potentially impacting its immunoassay product offerings, including ELISpot and Fluorospot assays. April 2024: U-CyTech Biosciences was recognized as a leading company in the ELISpot and Fluorospot assay market, significantly contributing to immunological research and clinical diagnostics. February 2024: Cellular Technology Limited (CTL) was identified as a major player in the ELISpot and Fluorospot assay market, with substantial contributions to assay development and distribution. Statistical Insights and Trends Reporting The United States accounted for approximately 40% of the global market share in 2023, driven by extensive research funding and strong healthcare infrastructure. The total number of ELISpot and Fluorospot assay kits and analyzers deployed worldwide is expected to increase by 70% between 2024 and 2032. The spending on immunology-based diagnostics, including ELISpot and Fluorospot assays, increased by 9.5% in 2023, reflecting the growing focus on early disease detection. The use of ELISpot and Fluorospot assays in immuno-oncology research is expected to grow by 85% by 2032, driven by increasing interest in personalized medicine and T-cell monitoring. Buy a Single-User PDF of ELISpot and Fluorospot Assay Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of Immune-related Diseases (2023) 5.2 Research and Clinical Adoption Trends, by Region (2023) 5.3 Assay Kit and Analyzer Volume, by Region (2020-2032) 5.4 Assay Kit and Analyzer Volume, by Region (2020-2032) 6. Competitive Landscape 7. ELISpot and Fluorospot Assay Market by Product 8. ELISpot and Fluorospot Assay Market by Application 9. ELISpot and Fluorospot Assay Market by End Use 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@

Johnson & Johnson rolls out TECNIS Odyssey IOL in selected regions
Johnson & Johnson rolls out TECNIS Odyssey IOL in selected regions

Yahoo

time7 hours ago

  • Yahoo

Johnson & Johnson rolls out TECNIS Odyssey IOL in selected regions

Johnson & Johnson (J&J) has introduced the TECNIS Odyssey IOL in the Middle East, Canada, and Europe, expanding its range of presbyopia-correcting intraocular lenses (PC-IOLs). This new lens is designed to provide patients with quality, continuous vision across all distances, significantly reducing the dependency on glasses. The TECNIS Odyssey IOL is built upon the TECNIS platform, which combines optics and materials to deliver clear, high-contrast vision. According to the company, it is designed to enhance visual freedom for patients, providing accurate vision for activities ranging from reading to driving. Individuals who have received the IOL reported they are satisfied with their overall vision without glasses. The IOL's freeform diffractive surface is engineered to provide seamless vision at near, intermediate, and far distances, with 96% of people satisfied with their ability to read on tablets or smartphones, and 97% with their distance vision. Additionally, the TECNIS Odyssey IOL is designed to reduce night vision disturbances such as glare and halos, offering improved image quality than PanOptix both day and night. It was observed that 92% of individuals expressed satisfaction with their ability to see steps and read street signs at night. The company's portfolio in the Middle East, Europe, Japan and Canada now includes both the TECNIS Odyssey IOL and the TECNIS PureSee IOL. While the TECNIS Odyssey is also available in Japan, the US, and Puerto Rico, the TECNIS PureSee is offered across Latin America and Asia-Pacific but has not yet received PMA approval in the US. J&J Vision Company Group chairman Peter Menziuso said: 'TECNIS Odyssey IOL is the fastest growing PC-IOL in the US, and we are excited to be making it available to more patients around the world. It addresses a significant unmet need for cataract patients seeking greater spectacle independence.' In recent news, J&J MedTech introduced the ETHICON 4000 Stapler, a surgical device designed to manage tissue complexities and ensure staple line integrity during surgeries. "Johnson & Johnson rolls out TECNIS Odyssey IOL in selected regions" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store